BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1001 related articles for article (PubMed ID: 23457043)

  • 1. MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development.
    Zhang X; Li D; Li M; Ye M; Ding L; Cai H; Fu D; Lv Z
    Int J Cancer; 2014 Jan; 134(2):257-67. PubMed ID: 23457043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear factor-{kappa}B contributes to anaplastic thyroid carcinomas through up-regulation of miR-146a.
    Pacifico F; Crescenzi E; Mellone S; Iannetti A; Porrino N; Liguoro D; Moscato F; Grieco M; Formisano S; Leonardi A
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1421-30. PubMed ID: 20061417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA miR-146b-5p regulates signal transduction of TGF-β by repressing SMAD4 in thyroid cancer.
    Geraldo MV; Yamashita AS; Kimura ET
    Oncogene; 2012 Apr; 31(15):1910-22. PubMed ID: 21874046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.
    Ma Y; Qin H; Cui Y
    Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid hormone receptor beta (THRB) is a major target gene for microRNAs deregulated in papillary thyroid carcinoma (PTC).
    Jazdzewski K; Boguslawska J; Jendrzejewski J; Liyanarachchi S; Pachucki J; Wardyn KA; Nauman A; de la Chapelle A
    J Clin Endocrinol Metab; 2011 Mar; 96(3):E546-53. PubMed ID: 21159845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Family of microRNA-146 Regulates RARβ in Papillary Thyroid Carcinoma.
    Czajka AA; Wójcicka A; Kubiak A; Kotlarek M; Bakuła-Zalewska E; Koperski Ł; Wiechno W; Jażdżewski K
    PLoS One; 2016; 11(3):e0151968. PubMed ID: 27011326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-146a modulates B-cell oncogenesis by regulating Egr1.
    Contreras JR; Palanichamy JK; Tran TM; Fernando TR; Rodriguez-Malave NI; Goswami N; Arboleda VA; Casero D; Rao DS
    Oncotarget; 2015 May; 6(13):11023-37. PubMed ID: 25906746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma.
    Chou CK; Yang KD; Chou FF; Huang CC; Lan YW; Lee YF; Kang HY; Liu RT
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E196-205. PubMed ID: 23264400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland?
    Lassalle S; Hofman V; Ilie M; Bonnetaud C; Puisségur MP; Brest P; Loubatier C; Guevara N; Bordone O; Cardinaud B; Lebrigand K; Rios G; Santini J; Franc B; Mari B; Al Ghuzlan A; Vielh P; Barbry P; Hofman P
    Endocr Relat Cancer; 2011 Oct; 18(5):579-94. PubMed ID: 21778212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
    Degl'Innocenti D; Romeo P; Tarantino E; Sensi M; Cassinelli G; Catalano V; Lanzi C; Perrone F; Pilotti S; Seregni E; Pierotti MA; Greco A; Borrello MG
    Endocr Relat Cancer; 2013 Feb; 20(1):23-37. PubMed ID: 23132790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of miR-138 sustains NF-κB activation and promotes lipid raft formation in esophageal squamous cell carcinoma.
    Gong H; Song L; Lin C; Liu A; Lin X; Wu J; Li M; Li J
    Clin Cancer Res; 2013 Mar; 19(5):1083-93. PubMed ID: 23319823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysine-Specific Demethylase 1 Affects the Progression of Papillary Thyroid Carcinoma via HIF1α and microRNA-146a.
    Long M; Zhu Y; Chen Z; Lin S; Peng X; Luo D; Li H; Tan L
    J Clin Endocrinol Metab; 2020 Jul; 105(7):. PubMed ID: 32303750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-128 suppresses the growth of thyroid carcinoma by negatively regulating SPHK1.
    Cao XZ; Bin H; Zang ZN
    Biomed Pharmacother; 2019 Jan; 109():1960-1966. PubMed ID: 30551451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long Noncoding RNA HOXA-AS2 Promotes Papillary Thyroid Cancer Progression by Regulating miR-520c-3p/S100A4 Pathway.
    Xia F; Chen Y; Jiang B; Du X; Peng Y; Wang W; Huang W; Feng T; Li X
    Cell Physiol Biochem; 2018; 50(5):1659-1672. PubMed ID: 30384358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-20b Displays Tumor-Suppressor Functions in Papillary Thyroid Carcinoma by Regulating the MAPK/ERK Signaling Pathway.
    Hong S; Yu S; Li J; Yin Y; Liu Y; Zhang Q; Guan H; Li Y; Xiao H
    Thyroid; 2016 Dec; 26(12):1733-1743. PubMed ID: 27717302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-29a suppresses growth and metastasis in papillary thyroid carcinoma by targeting AKT3.
    Li R; Liu J; Li Q; Chen G; Yu X
    Tumour Biol; 2016 Mar; 37(3):3987-96. PubMed ID: 26482618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-96 plays an oncogenic role by targeting FOXO1 and regulating AKT/FOXO1/Bim pathway in papillary thyroid carcinoma cells.
    Song HM; Luo Y; Li DF; Wei CK; Hua KY; Song JL; Xu H; Maskey N; Fang L
    Int J Clin Exp Pathol; 2015; 8(9):9889-900. PubMed ID: 26617698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-183 regulates biological behavior in papillary thyroid carcinoma by targeting the programmed cell death 4.
    Wei C; Song H; Sun X; Li D; Song J; Hua K; Fang L
    Oncol Rep; 2015 Jul; 34(1):211-20. PubMed ID: 26063221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-204-5p suppresses cell proliferation by inhibiting IGFBP5 in papillary thyroid carcinoma.
    Liu L; Wang J; Li X; Ma J; Shi C; Zhu H; Xi Q; Zhang J; Zhao X; Gu M
    Biochem Biophys Res Commun; 2015 Feb; 457(4):621-6. PubMed ID: 25603050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma.
    Minna E; Romeo P; De Cecco L; Dugo M; Cassinelli G; Pilotti S; Degl'Innocenti D; Lanzi C; Casalini P; Pierotti MA; Greco A; Borrello MG
    Oncotarget; 2014 May; 5(9):2513-28. PubMed ID: 24810336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.